{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:55:38Z","timestamp":1787496938251,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ygyno.2023.06.001","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T11:07:40Z","timestamp":1686827260000},"page":"60-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States"],"prefix":"10.1016","volume":"175","author":[{"given":"Jason N.","family":"Silberman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra S.","family":"Bercow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison A.","family":"Gockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Eisenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Sisodia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela G.","family":"del Carmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annekathryn","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar M.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Bregar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2023.06.001_bb0005","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ygyno.2018.03.001","article-title":"Meigs to modern times: the evolution of debulking surgery in advanced ovarian cancer","volume":"149","author":"Schorge","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.06.001_bb0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.06.001_bb0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jamaoncol.2016.4411","article-title":"Overall survival following neoadjuvant chemotherapy vs primary cytoreductive surgery in women with epithelial ovarian cancer: analysis of the National Cancer Database","volume":"3","author":"Rauh-Hain","year":"2017","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2023.06.001_bb0020","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2023.06.001_bb0025","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"10","key":"10.1016\/j.ygyno.2023.06.001_bb0030","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.06.001_bb0035","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2020.02.020","article-title":"Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers in phase III randomised trial","volume":"130","author":"Onda","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"9990","key":"10.1016\/j.ygyno.2023.06.001_bb0040","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet."},{"issue":"9","key":"10.1016\/j.ygyno.2023.06.001_bb0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.17517","article-title":"Trends in primary treatment and median survival among women with advanced-stage epithelial ovarian cancer in the US from 2004 to 2016","volume":"3","author":"Knisely","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/j.ygyno.2023.06.001_bb0050","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2016.09.002","article-title":"Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States","volume":"143","author":"Melamed","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.06.001_bb0055","article-title":"Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study","volume":"360","author":"Melamed","year":"2018","journal-title":"BMJ."},{"issue":"12","key":"10.1016\/j.ygyno.2023.06.001_bb0060","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/jamaoncol.2021.4252","article-title":"Association between overall survival and the tendency for cancer programs to administer neoadjuvant chemotherapy for patients with advanced ovarian cancer","volume":"7","author":"Melamed","year":"2021","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.06.001_bb0065","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2023.06.001_bb0070","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2023.06.001_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092345","article-title":"Surgical implications of advanced low-grade serous ovarian cancer: analysis of the database of the Tumeurs Malignes Rares Gyn\u00e9cologiques Network","volume":"14","author":"Bonsang-Kitzis","year":"2022","journal-title":"Cancers (Basel)."},{"issue":"3","key":"10.1016\/j.ygyno.2023.06.001_bb0080","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO study group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"2 Pt 1","key":"10.1016\/j.ygyno.2023.06.001_bb0085","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/AOG.0b013e31829ce7ec","article-title":"Survival in women with grade 1 serous ovarian carcinoma","volume":"122","author":"Nickles Fader","year":"2013","journal-title":"Obstet. Gynecol."},{"issue":"24","key":"10.1016\/j.ygyno.2023.06.001_bb0090","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1200\/JCO.2015.61.0873","article-title":"Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor","volume":"33","author":"Gershenson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.06.001_bb0095","series-title":"NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer: Version 1.2021","author":"National Comprehensive Cancer Network","year":"2023"},{"issue":"8","key":"10.1016\/j.ygyno.2023.06.001_bb0100","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/jso.21173","article-title":"Using the NCDB for cancer care improvement: an introduction to available quality assessment tools","volume":"99","author":"Raval","year":"2009","journal-title":"J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.06.001_bb0105","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1186\/s12885-022-10288-x","article-title":"Surgical outcomes of ureteral reconstruction during cytoreductive surgery for ovarian cancer: a retrospective cohort study","volume":"22","author":"Kim","year":"2022","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2023.06.001_bb0110","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ygyno.2006.03.028","article-title":"Splenectomy as part of cytoreductive surgery in ovarian cancer","volume":"102","author":"Magtibay","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.06.001_bb0115","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ygyno.2017.10.038","article-title":"Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer","volume":"148","author":"Hinchcliff","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2023.06.001_bb0120","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/IGC.0000000000000967","article-title":"Factors predicting use of neoadjuvant chemotherapy compared with primary Debulking surgery in advanced stage ovarian Cancer-a National Cancer Database Study","volume":"27","author":"Leiserowitz","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2023.06.001_bb0125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/AOG.0000000000001196","article-title":"Ovarian cancer treatment and survival trends among women older than 65 years of age in the United States, 1995-2008","volume":"127","author":"Lin","year":"2016","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.06.001_bb0130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2013.01.012","article-title":"Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?","volume":"129","author":"Worley","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.06.001_bb0135","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/jso.23171","article-title":"Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO stage IIIC and IV)","volume":"107","author":"Glasgow","year":"2013","journal-title":"J. Surg. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2023.06.001_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153681","article-title":"Traditional systemic treatment options in advanced low-grade serous ovarian cancer after successful Cytoreduction: a systematic review and meta-analysis","volume":"14","author":"Montero-Mac\u00edas","year":"2022","journal-title":"Cancers (Basel)."},{"issue":"3","key":"10.1016\/j.ygyno.2023.06.001_bb0145","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ygyno.2020.06.498","article-title":"The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: further evidence of relative chemoresistance","volume":"158","author":"Cobb","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"Supp 3","key":"10.1016\/j.ygyno.2023.06.001_bb0150","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/IGC.0000000000000257","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas","volume":"24","author":"Gourley","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2023.06.001_bb0155","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2019.30.e4","article-title":"The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer","volume":"30","author":"Bogani","year":"2019","journal-title":"J. Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2023.06.001_bb0160","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2023.06.001_bb0175","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ajog.2007.10.495","article-title":"Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer","volume":"197","author":"Aletti","year":"2007","journal-title":"Am. J. Obstet. Gynecol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823003281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823003281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T20:53:22Z","timestamp":1715806402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823003281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":33,"alternative-id":["S0090825823003281"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.06.001","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}